| Detected | Trial | Change |
|---|---|---|
| 2026-08-16 | NCT05999214 99mTc-H7ND SPECT/CT Imaging in NSCLC · First Affiliated Hospital Xi'an Jiaotong University |
overall status: Recruiting → Unknown |
| 2026-08-15 | NCT06627647 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for… · AstraZeneca |
Trial sites expanded: 287 -> 295 locations |
| 2026-08-15 | NCT05758116 Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in… · Peking University Cancer Hospital & Institute |
Trial completed |
| 2026-08-15 | NCT05758116 Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in… · Peking University Cancer Hospital & Institute |
Enrollment reduced: 20 -> 5 participants |
| 2026-08-15 | NCT05758116 Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in… · Peking University Cancer Hospital & Institute |
date change Primary completion pushed: 2025-07-07 -> 2026-06-30 |
| 2026-08-15 | NCT06822543 A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for… · Latin American Cooperative Oncology Group |
Trial sites expanded: 1 -> 13 locations |
| 2026-08-15 | NCT06694454 Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab… · National Cancer Institute (NCI) |
critical Recruitment suspended |
| 2026-08-15 | NCT06694454 Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab… · National Cancer Institute (NCI) |
critical Recruitment suspended: Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment. |
| 2026-08-15 | NCT04858958 Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation · Allist Pharmaceuticals, Inc. |
Trial completed |
| 2026-08-15 | NCT04858958 Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation · Allist Pharmaceuticals, Inc. |
Enrollment increased: 30 -> 90 participants |
| 2026-08-15 | NCT04858958 Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation · Allist Pharmaceuticals, Inc. |
date change Completion moved earlier: 2026-02-28 -> 2025-06-25 |
| 2026-08-14 | NCT04603807 A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants… · Hoffmann-La Roche |
date change Primary completion moved earlier: 2028-06-26 -> 2026-09-30 |
| 2026-08-14 | NCT04603807 A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants… · Hoffmann-La Roche |
date change Completion moved earlier: 2028-06-26 -> 2028-01-29 |
| 2026-08-14 | NCT03782207 A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions… · Hoffmann-La Roche |
Trial completed |
| 2026-08-14 | NCT05288205 Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors… · Allist Pharmaceuticals, Inc. |
date change Primary completion pushed: 2026-03 -> 2027-03 |
| 2026-08-14 | NCT05288205 Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors… · Allist Pharmaceuticals, Inc. |
date change Completion pushed: 2026-03 -> 2027-03 |
| 2026-08-14 | NCT05920356 A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum… · Amgen |
Trial sites expanded: 407 -> 412 locations |
| 2026-08-14 | NCT06416410 JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced… · Allist Pharmaceuticals, Inc. |
date change Primary completion pushed: 2026-09-30 -> 2029-09-30 |
| 2026-08-14 | NCT06416410 JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced… · Allist Pharmaceuticals, Inc. |
date change Completion pushed: 2027-02-28 -> 2030-08 |
| 2026-08-14 | NCT05872763 A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be… · Hoffmann-La Roche |
Trial completed |
| First Posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-08-10 | NCT07755397 First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety… | Jubilant Therapeutics India Limited NEW | Phase 1 |
| 2026-08-07 | NCT07751536 ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With… | Shuanghu Yuan NEW | |
| 2026-08-03 | NCT07742800 Multi-Omics Prediction of Radiation Lung Injury in Immunotherapy-Treated Lung Cancer… | HAN GUANG NEW | |
| 2026-08-03 | NCT07743021 Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data | Center for Molecular Fingerprinting Research Nonprofit LLC NEW | |
| 2026-07-20 | NCT07714304 JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC | Huan Zhou NEW | |
| 2026-07-17 | NCT07710599 LKB1 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer: A Retrospective… | Ling Zhiqiang NEW | |
| 2026-07-15 | NCT07704658 Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | Rigel Pharmaceuticals NEW | Phase 4 |
| 2026-07-15 | NCT07705334 A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic… | SHY Therapeutics NEW | Phase 1 |
| 2026-07-13 | NCT07699328 A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer | Voronoi, Inc NEW | Phase 1/2 |
| 2026-07-13 | NCT07697716 In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing | Fondazione Policlinico Universitario Agostino Gemelli IRCCS NEW |
| NCT ID | Title | Sponsor | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05172739 | Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in… | University of Crete | Recruiting |
| NCT05525338 | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib… | University Medical Center Groningen | Recruiting |
| NCT05748093 | Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With… | Maastricht University Medical Center | Recruiting |
| NCT06908070 | Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab | Idris Bahce | Recruiting |
| NCT07092202 | Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC… | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting |
| NCT07320105 | Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy… | Fujian Cancer Hospital | Recruiting |
| NCT06330038 | Anesthesia and Non-small Cell Lung Cancer Recurrence | Samsung Medical Center | Recruiting |
| NCT06646471 | PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With… | GFPC Investigation | Recruiting |
| NCT07279935 | Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After… | AstraZeneca | Recruiting |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or… | OHSU Knight Cancer Institute | Recruiting |
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | Novartis Pharmaceuticals | Recruiting |
| NCT07744698 | Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer… | Anhui Provincial Cancer Hospital | Recruiting |
| NCT07704658 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | Rigel Pharmaceuticals | Recruiting |
| NCT07754812 | Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment… | Shanghai Pulmonary Hospital, Shanghai, China | Recruiting |
| NCT06356675 | A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With… | The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | Not Yet Recruiting |
| NCT06483009 | Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With… | Shanghai Chest Hospital | Not Yet Recruiting |
| NCT06785584 | Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable… | Fujian Medical University Union Hospital | Not Yet Recruiting |
| NCT04413201 | AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib… | Michael Hopp | Active, Not Recruiting |
| NCT06893354 | Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance… | The First Affiliated Hospital of Guangzhou Medical University | Not Yet Recruiting |
| NCT05144997 | Lorlatinib Continuation Study | Pfizer | Active, Not Recruiting |
| NCT05689671 | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung… | Nikolaj Frost MD | Active, Not Recruiting |
| NCT07469488 | A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM)… | Shanghai Pulmonary Hospital, Shanghai, China | Not Yet Recruiting |
| NCT05160922 | Crizotinib Continuation Clinical Study | Pfizer | Active, Not Recruiting |
| NCT06282874 | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases | Guangdong Association of Clinical Trials | Active, Not Recruiting |
| NCT07633613 | Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor… | Centre Antoine Lacassagne | Not Yet Recruiting |